Base to Base Biotech

Jim Cornall
  • 0.0 (0)
  • Medicine
  • Updated weekly

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.

  1. 5 days ago

    Base to Base biotech podcast 70: Taking the lead on GI motility disorders

    This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders. Renexxion Renexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical company, with a subsidiary in Ireland, committed to developing new therapies for patients with gastrointestinal disorders. Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract. Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion recently announced positive results from MOVE-IT, a global phase 2b, randomised placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 70: Taking the lead on GI motility disorders

  2. 24 Jul

    Base to Base biotech podcast 69: nrHSV-1 technology and environmental testing through hair

    Times: 01:33 Cyllene Tx 21:37 LinusBio This week, we have conversations with LinusBio founder and Mt. Sinai environmental professor, Dr. Manish Arora, as well as with Philippe Chambon, CEO of Cyllene Therapeutics (Cyllene Tx). Cyllene Therapeutics Cyllene Therapeutics is a global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. It is currently executing a phase 1/2 study in the US with its lead DNA medicine candidate, EG110A, in patients with neurogenic detrusor overactivity (neurogenic bladder)-related incontinence. This is the first human study with nrHSV vectors targeting sensory neuron-based diseases. EG110A is being developed to address multiple severe bladder diseases, including overactive bladder (OAB), and has the potential to be a major improvement over existing therapies, resulting in better care for patients and lower costs for healthcare systems. The company's HERMES platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Its vectors can achieve focal transduction and then selective expression of transgenes in targeted subsets of neurons. With demonstrated clinical safety and possible repeat dosing, the large payload capacity of nrHSV-1 vectors allows for versatile DNA delivery and smarter DNA medicine. LinusBio LinusBio’s Traced, which launched this month, is the first direct-to-consumer wellness test that uses a single strand of hair to provide a day-by-day view of exposure to 15 elements—including nutrients like zinc and magnesium, as well as toxic elements such as lead, arsenic, cadmium, and aluminium—over the course of 30 days. Traced uses LinusBio's proprietary platform, combining advanced robotics, laser ablation, and mass spectrometry to identify exposure patterns over time. Traced provides consumers with a 30-day history of all measured exposures. Levels are measured relative to LinusBio's proprietary global reference database. It is not a measure of health or a diagnosis of any condition; it's meant to inform consumers and empower them to take steps to mitigate their exposure. Developed from research at Mount Sinai, Traced offers a different approach than traditional blood or urine testing by showing how exposures change over time and helping consumers connect those patterns to their daily routines, travel, homes, and environments. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 69: nrHSV-1 technology and environmental testing through hair

  3. 17 Jul

    Base to Base biotech podcast 68: Water from air for pharma and beyond

    This week, we have a conversation with Kyle Cordova, founder and CEO of AquaPoro. AquaPoro AquaPoro is a deeptech company engineering systems that can harvest water from the atmosphere based in California that was spun out of Jordan's Royal Scientific Society. Atmospheric water generators (AWGs) aren't uncommon as freshwater becomes scarcer for use in a variety of industries from food and beverages to pharmaceutical companies. AquaPoro's approach is different. Traditional AWGs require more than 60% humidity to function. AquaPoro's can function with less than 10%. Its atmospheric low-humidity moisture adsorption (ALMA) technology, based on Nobel Prize winning chemistry frameworks, extracts water from ambient air at lower energy and cost, regardless of temperature or humidity. Its process is continuous, and its modular "Stream" systems integrate directly into manufacturing facilities for more efficient output. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 68: Water from air for pharma and beyond

  4. 10 Jul

    Base to Base biotech podcast 67: Synthetic DNA and crossing the blood-brain barrier

    Times: 02:58 Deep Science Ventures 22:16 4basebio This week, we have a conversation with Amy Walker, CEO of 4basebio, and Adam Tomassi-Russell, senior director, climate, at Deep Science Ventures. 4basebio 4basebio is a UK-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently. Deep Science Ventures Deep Science Ventures (DSV) is a venture creator building deeptech companies in four sectors: agriculture, climate, computation and pharmaceuticals. For just under a decade, DSV has pioneered venture creation through funded partnerships with organisations like Coca-Cola, AbbVie, Anglo American, the Advanced Research and Invention Agency (ARIA) and Cancer Research UK. DSV and Medicines Discovery Catapult (MDC), a life sciences service dedicated to turning drug discovery into commercial breakthroughs, recently announced a strategic collaboration to address challenges in delivering medicines into the brain. DSV's portfolio, worth more than $700m, has raised more than $270m from investors including Breakthrough Energy Ventures, Lowercarbon Capital, Sequoia, Sam Altman, and Patrick Collison. DSV is a global team of scientists and exited founders based in London, Tokyo, and Boston, with backgrounds from Bell Labs, Imperial College, and Intel. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

  5. 3 Jul

    Base to Base biotech podcast 66: The future of clinical trials and breakthroughs in molecular testing

    This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies, founder and CEO of Luvida. Times: 03:03 Longhorn Vaccines and Diagnostics 25:03 Luvida Longhorn Vaccines & Diagnostics on breakthroughs in molecular testing Maryland-based Longhorn Vaccines and Diagnostics is a IND-enabling stage biopharmaceutical company developing vaccines, monoclonal antibodies, and diagnostics targeting pathogens. The company focuses on innovative approaches to addressing major public health challenges including antimicrobial resistance, sepsis, and inflammatory disease. Started in 2006 with the invention of inactivating molecular transport media for collection of respiratory samples and the stabilization of nucleic acid at ambient temperature for weeks to months, Longhorn created the product category and the predicate device at the U. S. Food and Drug Administration. Luvida – solving clinical trial bottlenecks Luvida is an AI data platform that helps pharma, biotech, and CRO teams design clinical trials. Most trials don’t fail because of bad science. The biology is well understood, but the factors that drive recruitment, adherence, and drop-out aren’t used at scale. Luvida solves this with proprietary Electronic Life Records, a data layer that captures how patients live, and uses explainable AI to surface trial risk before a single patient is enrolled. The result is faster, data-driven protocols, with fewer costly amendments, and trials that complete faster. Ultimately, this means medicines that reach patients sooner. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 66: The future of clinical trials and breakthroughs in molecular testing

  6. 26 Jun

    Base to Base biotech podcast 65: Giving medicine a genetic camouflage

    This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold. Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an oversubscribed pre-seed round. The funding enables Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time. The platform- a machine learning-guided DNA sequence design infrastructure- is engineered to overcome the biological barriers limiting genetic medicines. Positioned for rapid commercial scaling ahead of its next funding round, Houdini Bio provides the infrastructure required to make genetic medicines work durably, consistently and cost-efficiently at scale- transforming outcomes for patients suffering from blindness, cystic fibrosis, haemophilia, dementia, cancer and more. While gene and cell therapies are progressing rapidly, their real-world impact is held back by a fundamental biological hurdle: the human cell often mistakes therapeutic DNA for a viral invader. To protect itself, the cell triggers natural defences that 'silence' the medicine. This premature shutdown limits the treatment's long-term effectiveness, drives up manufacturing costs and demands high doses which can cause dangerous immune reactions in patients. Current industry attempts to keep these therapies active rely on trial-and-error experimentation, which is slow, costly and unreliable. Houdini Bio solves this problem at the level of the genetic code itself. By combining machine learning with a deep understanding of cellular defences- specifically a master silencing mechanism known as the human silencing hub (HUSH) complex - Houdini Bio has created a toolkit to re-engineer therapeutic DNA. This gives the medicine a genetic camouflage, preserving its medical purpose while making it invisible to the cell's defences. The platform uses advanced sequence design to reliably boost gene expression output by more than 10-fold compared to current state-of-the-art methods, ensuring therapies work more efficiently, at lower doses, for longer. The company's foundational science bridges academic discovery and industrial application. The HUSH complex was originally discovered by Paul Lehner at the University of Cambridge, who identified how the body silences foreign genetic material. Building on this breakthrough during his PhD in molecular genetics, Houdini Bio CEO and co-founder Jonathan Cohen-Gold discovered a novel set of molecular rules that allow certain DNA sequences to escape this cellular lock-down. Houdini Bio has accelerated these insights using AI, building an engineering platform that paves the way for more affordable, durable gene therapies and cell therapies like CAR-T. To drive its commercial strategy, Cohen-Gold is joined by co-founder and chief business officer Lee Dunham. Having worked with more than 100 cell and gene therapy companies over the past decade- including as a director of business development at Cell and Gene Therapy Catapult- Dunham has seen first-hand why promising therapies stall, founding Houdini Bio after recognising its unique ability to solve a huge industry challenge. With its platform fully validated ahead of schedule, the company will maintain momentum to expand its team and scale co-development partnerships with pharma companies, deep tech innovators and pioneering developers looking to integrate anti-silencing technology into next-generation drug pipelines. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 65: Giving medicine a genetic camouflage

  7. 19 Jun

    Base to Base biotech podcast 64: Solving logistics challenges

    This week on Base to Base, we have a conversation with Bora Pharmaceuticals’ chief commercial officer Jean-Baptiste (JB) Agnus. Bora Pharmaceuticals Bora Pharmaceuticals is an international contract development and manufacturing organization (CDMO) specialising in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. With sites in North America and Asia, they deliver drug products to more than 100 markets around the world. In May, Bora Group announced the acquisition of MacroGenics’ GMP manufacturing operations for $122.5m. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 64: Solving logistics challenges

  8. 12 Jun

    Base to Base biotech podcast 63: Cell and gene therapy logistics, and turning back the Parkinson’s clock

    This week, we have a conversation with Mark Sawicki, president and CEO of Cryoport Systems, and we chat with Nick Manusos, CEO of Kenai Therapeutics. Times: 03:22 Cryoport Systems 22:24 Kenai Therapeutics Cryoport Systems Cryoport Systems provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensitive biological materials used in biopharma development, reproductive medicine and animal health. Its services are designed to protect products and materials that require tightly controlled environments, including cell and gene therapies, biologics and reproductive specimens. The company offers an integrated platform that combines specialised shipping systems, logistics and transportation services, cryopreservation, biostorage and bioservices capabilities, and consulting support. Its solutions cover a range of temperature requirements, from cryogenic conditions below -150°C to refrigerated and controlled room-temperature environments. Cryoport Systems also provides monitoring and traceability technologies intended to maintain the integrity of materials throughout the supply chain. Cryoport Systems is part of Cryoport, Inc., a publicly traded company headquartered in Brentwood, Tennessee. Founded in 1999, Cryoport, Inc. serves customers globally through a family of companies that includes Cryoport Systems, MVE Biological Solutions and CRYOGENE. The organisation supports clinical and commercial programmes worldwide, with a particular focus on the temperature-controlled supply chain requirements of advanced therapies. Kenai Therapeutics Kenai Therapeutics recently announced a major milestone with the dosing of the first patient in its phase 1 clinical trial of RNDP-001. This approach is fundamentally disease-modifying, moving beyond symptom control to address the root cause of Parkinson's disease, and has the potential to be manufactured in large batches and readily available for more patients across the globe. Current Parkinson’s treatments focus almost entirely on managing the symptoms caused by the loss of dopamine-producing neurons. RNDP-001 represents a significant shift by aiming to replace those lost neurons, repair damaged neural circuits, and potentially restore motor function. Unlike patient-specific (autologous) therapies, RNDP-001 is an allogeneic (donor-derived), cryopreserved product built on a proprietary iPSC platform. This is a critical practical advancement, allowing the product to be manufactured in large batches and readily available for more patients, which is essential for global access. The therapy has been granted Fast Track designation by the U.S. FDA, acknowledging the urgent need for new treatments and the potential of RNDP-001 to address a serious unmet medical need. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 63: Cell and gene therapy logistics, and turning back the Parkinson’s clock
See All (70)

About

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.

Information

  • Creator
    Jim Cornall
  • Years Active
    2025 - 2026
  • Episodes
    70
  • Rating
    Clean
  • Copyright
    © Ayr Coastal Media Ltd 2025
  • Show Website
    Base to Base Biotech

You Might Also Like